Sun Pharma recalls 55000 bottles of generic drug to treat gout from American market
The affected lot was produced at Sun Pharma's Dadra-based plant for Memphis-based Northstar Rx LLC, the US regulator noted.
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-03-12 07:43 GMT | Update On 2024-03-19 12:03 GMT
Advertisement
Mumbai: Drug major Sun Pharma is recalling around 55,000 bottles of a generic medication to treat gout from the American market due to manufacturing practices norms deviations, according to the US health regulator.
The New Jersey-based unit of the Mumbai-based drug major is recalling Febuxostat Tablets in 40 mg and 80 mg strengths, US Food and Drug Administration (USFDA) said in its latest Enforcement Report.
Sun Pharmaceutical Industries Inc is recalling 47,520 bottles (40mg) and 7,488 bottles (80 mg) respectively of the medication due to Current Good Manufacturing Practice regulations (CGMP) deviations, it stated.
"Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment," the USFDA stated.
The affected lot was produced at Sun Pharma's Dadra-based plant for Memphis-based Northstar Rx LLC, the US regulator noted.
Febuxostat is used to lower uric acid levels in people with gout.
As per the USFDA, the company has initiated the Class II nationwide (US) recall on March 4 this year.
As per the USFDA, a class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Sun Pharma is one of the leading generic pharmaceutical companies in the US. The US generic drug market was estimated to be around $ 115.2 billion in 2019. It is the largest market for pharmaceutical products
Read also: Sun Pharma unit recalls over 54000 bottles of Mesalamine ER capsules in US
Original news source: https://www.ptinews.com/story/business/sun-pharma-recalls-55-000-bottles-of-generic-drug-from-us-market-due-to-manufacturing-norms-violation/1347602
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.